Roche (SIX: ROG) and the Medicines Patent Pool (MPP) announced the signing of a voluntary licence agreement covering baloxavir marboxil (Xofluza), Roche’s single-dose oral influenza antiviral, enabling generic manufacturers to produce and supply the drug across 129 low- and middle-income countries and establishing a tiered royalty structure that waives payments entirely for the world’s poorest nations. The agreement, announced publicly on 18 May during the 79th World Health Assembly in Geneva, grants MPP a non-exclusive, non-transferable licence to sublicense Roche’s full intellectual property package — including patents, know-how, and manufacturing data — to qualified generic producers in the licensed territory.
Baloxavir marboxil is a cap-dependent endonuclease inhibitor that blocks influenza virus replication at an early stage of the viral lifecycle, differentiating it mechanistically from neuraminidase inhibitors such as oseltamivir. The drug is approved by the US FDA and the European Medicines Agency for treatment of uncomplicated influenza and for post-exposure prophylaxis across age groups starting from three weeks of age under some regulatory labels. The WHO has included baloxavir marboxil in its clinical practice guidelines for influenza, and the compound is active against strains that are resistant to neuraminidase inhibitors, a characteristic that the parties cited as relevant to pandemic preparedness planning.
The agreement follows MPP’s standard two-tier architecture. Roche grants MPP a head licence, and MPP in turn issues standardized sublicences to approved generic manufacturers identified through an Expression of Interest process that MPP launched concurrently with the public announcement. Sublicensees must demonstrate manufacturing capacity consistent with WHO prequalification standards or the requirements of a stringent regulatory authority, and must commit to filing for regulatory approval before at least one relevant authority within 36 months of the sublicence effective date.
To support generic development, Roche committed to provide each sublicensee with a foundational data package covering formula and composition, manufacturing process descriptions, specifications, stability data, analytical method validation, and impurity discussion. Roche also agreed to supply reference product tablets — up to 100 tablets of the 40mg oral formulation and up to 550 tablets of the 80mg formulation — free of charge per sublicensee for use in bioequivalence studies and in vitro research. Roche will additionally waive data exclusivity and market exclusivity in the licensed territory to the extent required by applicable regulatory authorities for generic approvals to proceed.
Royalty terms and territorial scope
The royalty structure is tiered by World Bank country income classification. Low-income economies, as defined by the World Bank, are excluded from royalty obligations entirely. Sublicensees supplying lower-middle income economies pay 5% of net sales value, while those supplying upper-middle income economies pay 10%. A 40% rate applies if high-income economies are ever added to the territory, a provision primarily relevant to pandemic emergency scenarios.
Royalties are invoiced quarterly in Swiss francs, with payment due within 30 days of invoice receipt. Late payments accrue interest at the Swiss National Bank base rate plus 2% per annum, compounded monthly. Royalty obligations run on a product-by-product, country-by-country basis until the last valid patent expires in each jurisdiction, at which point the sublicence converts to a perpetual, royalty-free licence under the licensed know-how.